Literature DB >> 17631268

Photodynamic therapy with verteporfin for corneal neovascularization.

Kyung-Chul Yoon1, In-Cheon You, In-Seong Kang, Seong-Kyu Im, Jae-Kyoun Ahn, Yeoung-Geol Park, Kyu Youn Ahn.   

Abstract

PURPOSE: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization.
DESIGN: Prospective interventional case series.
METHODS: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment were treated with photodynamic therapy with verteporfin (6 mg/m(2)). Five patients were treated following penetrating keratoplasty (PK), and two patients were treated before PK. Anterior segment photography was performed before and after treatment. Best-corrected visual acuity (BCVA) and area of corneal neovascularization were measured.
RESULTS: At the one-year follow-up, 14 eyes (77.8%) showed a decrease in corneal neovascularization, and nine eyes (50.0%) showed complete vascular occlusion. In five patients who had corneal allograft, complete or partial occlusion was achieved in all eyes. Two patients who underwent subsequent keratoplasty did not manifest allograft rejection or revascularization. Seventeen eyes (94.4%) had stable or improved vision. The mean area of corneal neovascularization significantly decreased from 25.5 +/- 14.2 mm(2) to 14.9 +/- 14.6 mm(2) (P < .01), respectively. No significant complications associated with photodynamic therapy were observed except mild stromal haze in one eye.
CONCLUSION: Photodynamic therapy with verteporfin may be effective for the treatment of corneal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631268     DOI: 10.1016/j.ajo.2007.05.028

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Topographical alteration in the cornea after photodynamic therapy for neovascularization in lipid keratopathy.

Authors:  Tsutomu Igarashi; Chiemi Yaguchi; Michinori Inage; Hisaharu Suzuki; Hiroshi Takahashi
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

Review 2.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

3.  Femtosecond laser-assisted selective reduction of neovascularization in rat cornea.

Authors:  Mehra S Sidhu; Min-Yeong Choi; Suk-Yi Woo; Hyun-Kyu Lee; Heung-Soon Lee; Kyu-Jin Kim; Sae Chae Jeoung; Jun-Sub Choi; Choun-Ki Joo; Il-Hong Park
Journal:  Lasers Med Sci       Date:  2014-02-26       Impact factor: 3.161

4.  Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.

Authors:  Omar M Kirat; Hassan A Al-Dhibi
Journal:  Saudi J Ophthalmol       Date:  2010-05-27

Review 5.  Corneal transparency: genesis, maintenance and dysfunction.

Authors:  Yureeda Qazi; Gilbert Wong; Bryan Monson; Jack Stringham; Balamurali K Ambati
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

Review 6.  Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Authors:  David Ellenberg; Dimitri T Azar; Joelle A Hallak; Faisal Tobaigy; Kyu Yeon Han; Sandeep Jain; Zhongjun Zhou; Jin-Hong Chang
Journal:  Prog Retin Eye Res       Date:  2010-01-25       Impact factor: 21.198

7.  Photodynamic therapy with verteporfin for corneal neovascularization.

Authors:  Abdullah A Al-Torbak
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun

8.  Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis.

Authors:  Witold W Kilarski; Angelika Muchowicz; Malgorzata Wachowska; Renata Mężyk-Kopeć; Jakub Golab; Melody A Swartz; Patrycja Nowak-Sliwinska
Journal:  Angiogenesis       Date:  2013-07-28       Impact factor: 9.596

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.